微量残存疾病检测:全球市场和技术
市场调查报告书
商品编码
1317646

微量残存疾病检测:全球市场和技术

Minimal Residual Disease Testing: Global Markets and Technologies

出版日期: | 出版商: BCC Research | 英文 152 Pages | 订单完成后即时交付

价格

全球微量残存疾病检测市场预计将从2023年的22亿美元增长到2028年的43亿美元,预测期内年复合成长率为14.3%。

从技术角度来看,聚合酶炼式反应(PCR)行业将从2023年的9.959亿美元增长到2028年的20亿美元左右,预测期内年复合成长率为14.5%。下一代测序 (NGS) 领域预计将从 2023 年的 3.768 亿美元增长到 2028 年的 7.623 亿美元,年复合成长率为 15.1%。

本报告审视了全球微量残存疾病检测市场,提供了市场和技术背景、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析以及新兴技术。竞争状况、主要公司简介等

目录

第1章简介

第2章总结/要点

  • 市场预测

第3章市场概况

  • 微量残存疾病的定义
  • 微量残存疾病检测的重要性
  • 微量残存疾病检测的指征
  • 用于检测微量残存疾病的技术

第4章市场动态

  • 市场动态
  • 促进因素
  • 抑制因素
  • 机会
  • COVID-19对微量残存疾病检测市场的影响
  • 法律地位
  • 1988 年临床实验室改进修正案 (CLIA)
  • 州许可法
  • 美国FDA

第5章全球微量残存疾病检测市场(按技术)

  • 概述
  • 流式细胞术
  • 聚合酶炼式反应 (PCR)
  • 新一代测序 (NGS)
  • 其他的

第6章全球微量残存疾病检测市场(按用途)

  • 概述
  • 血液系统恶性肿瘤
  • 白血病
  • 淋巴瘤
  • 骨髓瘤
  • 实体瘤
  • 其他的

第7章全球微量残存疾病检测市场(按地区)

  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第8章ESG发展

  • ESG在微量残存疾病检测行业的重要性
  • ESG 评级和指标:了解数据
  • 微量残存疾病检测行业的ESG实践
  • 环保性能
  • 社会表现
  • 治理绩效
  • 未来趋势
  • BCC 研究的观点

第9章新技术和发展

  • 新技术
  • 数字聚合酶炼式反应 (dPCR)

第10章併购分析

第11章竞争信息

  • 主要企业排名
  • 公司的关键战略
  • 合作
  • 营销活动
  • 新产品发布
  • 扩张
  • 获得
  • 伙伴关係、合作、联合
  • 临床数据研究
  • 其他的

第12章公司简介

  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • AMGEN INC.
  • ASTRAZENECA PLC
  • BIO-RAD LABORATORIES INC.
  • CERGENTIS BV
  • EXACT SCIENCES CORP.
  • GUARDANT HEALTH INC.
  • ILLUMINA INC. (GRAIL LLC)
  • INVITAE
  • INVIVOSCRIBE INC.
  • NATERA INC.
  • NEOGENOMICS INC.
  • QIAGEN
  • SYSMEX CORP.
Product Code: PHM275A

Highlights:

The global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028, at a compound annual growth rate (CAGR) of 14.3% from 2023 through 2028.

The global market for polymerase chain reaction for minimal residual disease testing is estimated to increase from $995.9 million in 2023 to reach about $2.0 billion by 2028, at a CAGR of 14.5% from 2023 through 2028.

The global market for next-generation sequencing (NGS) for minimal residual disease testing is estimated to increase from $376.8 million in 2023 to reach $762.3 million by 2028, at a CAGR of 15.1% from 2023 through 2028.

Report Scope:

The report's scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies' mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Report Includes:

  • 44 data tables and 45 additional tables
  • An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
  • Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
  • In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
  • Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
  • Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
  • Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
  • A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
  • Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Research Methodology
  • Information Sources
  • Geographic Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook

Chapter 3 Market Overview

  • Definition of Minimal Residual Disease
  • Importance of Detecting Minimal Residual Disease
  • Indications for Minimal Residual Disease Testing
  • Techniques Used for Detecting Minimal Residual Disease

Chapter 4 Market Dynamics

  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Impact of Covid-19 on Minimal Residual Disease Testing Market
  • Regulatory Landscape
  • Clinical Laboratory Improvement Amendments of 1988 (CLIA)
  • State Licensing Laws
  • The U.S. Food and Drug Administration

Chapter 5 Global Minimal Residual Disease Testing Market by Technology

  • Overview
  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Others

Chapter 6 Global Minimal Residual Disease Testing Market by Application

  • Overview
  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Myeloma
  • Solid Tumors
  • Others

Chapter 7 Global Minimal Residual Disease Testing Market by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 8 ESG Developments

  • Importance of ESG in Minimal Residual Disease Testing Industry
  • ESG Ratings and Metrics: Understanding the Data
  • ESG Practices in the Minimal Residual Disease Testing Industry
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Future Trends
  • BCC Research Viewpoint

Chapter 9 Emerging Technologies and Developments

  • Emerging Technologies
  • Digital Polymerase Chain Reaction (dPCR)

Chapter 10 M&A Analysis

  • M&A Analysis

Chapter 11 Competitive Intelligence

  • Top Market Players Ranking, 2022
  • Key Strategies Adopted by Companies
  • Collaborations
  • Marketing Activity
  • New Product Launch
  • Expansion
  • Acquisition
  • Partnerships, Agreements and Alliances
  • Clinical Data Studies
  • Others

Chapter 12 Company Profiles

  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • AMGEN INC.
  • ASTRAZENECA PLC
  • BIO-RAD LABORATORIES INC.
  • CERGENTIS B.V.
  • EXACT SCIENCES CORP.
  • GUARDANT HEALTH INC.
  • ILLUMINA INC. (GRAIL LLC)
  • INVITAE
  • INVIVOSCRIBE INC.
  • NATERA INC.
  • NEOGENOMICS INC.
  • QIAGEN
  • SYSMEX CORP.

List of Tables

  • Summary Table : Global Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 1 : Techniques to Quantify MRD in Multiple Myeloma
  • Table 2 : Advantages and Disadvantages of Available Techniques to Monitor MRD
  • Table 3 : Various Liquid Biopsies for Minimal Residual Disease Testing
  • Table 4 : Total Number of New Cancer Cases and Deaths Due to Various Cancers Globally, 2020
  • Table 5 : Global Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 6 : Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, Through 2028
  • Table 7 : Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, Through 2028
  • Table 8 : Global Market for Next-Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, Through 2028
  • Table 9 : Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, Through 2028
  • Table 10 : Global Market for Minimal Residual Disease Testing, by Application, Through 2028
  • Table 11 : Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, Through 2028
  • Table 12 : Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
  • Table 13 : Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, Through 2028
  • Table 14 : Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, Through 2028
  • Table 15 : Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, Through 2028
  • Table 16 : Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, Through 2028
  • Table 17 : Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, Through 2028
  • Table 18 : Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, Through 2028
  • Table 19 : Global Market for Minimal Residual Disease Testing for Solid Tumors, by Region, Through 2028
  • Table 20 : Global Market for Minimal Residual Disease Testing for Other Applications, by Region, Through 2028
  • Table 21 : Global Market for Minimal Residual Disease Testing, by Region, Through 2028
  • Table 22 : North American Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 23 : North American Market for Minimal Residual Disease Testing, by Application, Through 2028
  • Table 24 : North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
  • Table 25 : Estimated Cancer Incidence and Mortality, Age Standardized Rate, by Cancer Type, EU Countries, 2020
  • Table 26 : European Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 27 : European Market for Minimal Residual Disease Testing, by Application, Through 2028
  • Table 28 : European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
  • Table 29 : Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 30 : Asia-Pacific Market for Minimal Residual Disease Testing, by Application, Through 2028
  • Table 31 : Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
  • Table 32 : Rest of the World Market for Minimal Residual Disease Testing, by Technology, Through 2028
  • Table 33 : Rest of the World Market for Minimal Residual Disease Testing, by Application, Through 2028
  • Table 34 : Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
  • Table 35 : ESG Ratings and Metrics
  • Table 36 : Environmental Performance in the Minimal Residual Disease Testing Industry
  • Table 37 : Social Performance in the Minimal Residual Disease Testing Industry
  • Table 38 : Governance Performance in the Minimal Residual Disease Testing Industry
  • Table 39 : Acquisitions in the Minimal Residual Disease Testing Industry, Oct. 2020-Apr. 2023
  • Table 40 : Collaborations: Minimal Residual Disease Testing Market, 2020-2023
  • Table 41 : Marketing Activity: Minimal Residual Disease Testing Market, 2020-2023
  • Table 42 : New Product Launch: Minimal Residual Disease Testing Market, 2020-2023
  • Table 43 : Expansion: Minimal Residual Disease Testing Market, 2020-2023
  • Table 44 : Acquisitions: Minimal Residual Disease Testing Market, 2020-2023
  • Table 45 : Partnerships, Agreements and Alliances: Minimal Residual Disease Testing Market, 2020-2023
  • Table 46 : Clinical Data Studies: Minimal Residual Disease Testing Market, 2020-2023
  • Table 47 : Other Competitive Strategies: Minimal Residual Disease Testing Market, 2020-2023
  • Table 48 : Adaptive Biotechnologies Corp.: Annual Revenue, 2022
  • Table 49 : Adaptive Biotechnologies Corp.: Recent Developments, Nov. 2020-Apr. 2023
  • Table 50 : Adaptive Biotechnologies Corp.: Pipeline Products
  • Table 51 : Adaptive Biotechnologies Corp.: Product Portfolio
  • Table 52 : Amgen Inc.: Annual Revenue, 2022
  • Table 53 : Amgen Inc.: Recent Developments, 2019-2023
  • Table 54 : Amgen Inc.: Product Portfolio
  • Table 55 : AstraZeneca Plc: Annual Revenue, 2022
  • Table 56 : AstraZeneca Plc: Recent Developments, 2020-2023
  • Table 57 : AstraZeneca Plc: Product Portfolio
  • Table 58 : Bio-Rad Laboratories Inc.: Annual Revenue, 2022
  • Table 59 : Bio-Rad Laboratories Inc.: Recent Developments, 2022 and 2023
  • Table 60 : Bio-Rad Laboratories Inc.: Product Portfolio
  • Table 61 : Cergentis B.V.: Recent Developments, 2020-2022
  • Table 62 : Cergentis B.V.: Product Portfolio
  • Table 63 : Exact Sciences Corp.: Annual Revenue, 2021
  • Table 64 : Exact Sciences Corp.: Recent Developments, 2021-2023
  • Table 65 : Exact Sciences Corp.: Product Portfolio
  • Table 66 : Guardant Health Inc.: Annual Revenue, 2022
  • Table 67 : Guardant Health Inc.: Recent Developments, 2021-2023
  • Table 68 : Guardant Health Inc.: Product Portfolio
  • Table 69 : Illumina Inc.: Annual Revenue, 2022
  • Table 70 : Illumina, Inc.: Recent Developments, 2021-2023
  • Table 71 : Illumina Inc.: Product Portfolio
  • Table 72 : Invitae: Annual Revenue, 2022
  • Table 73 : Invitae: Recent Developments, 2020-2023
  • Table 74 : Invitae: Product Portfolio
  • Table 75 : Invivoscribe Inc.: Recent Developments, 2021-2023
  • Table 76 : Invivoscribe Inc.: Product Portfolio
  • Table 77 : Natera Inc.: Annual Revenue, 2022
  • Table 78 : Natera Inc.: Recent Developments, 2022 and 2023
  • Table 79 : Natera Inc.: Product Portfolio
  • Table 80 : NeoGenomics Inc.: Annual Revenue, 2022
  • Table 81 : NeoGenomics Inc.: Recent Developments, 2021-2023
  • Table 82 : NeoGenomics Inc.: Product Portfolio
  • Table 83 : Qiagen N.V.: Annual Revenue, 2022
  • Table 84 : Qiagen N.V.: Recent Developments, 2021-2023
  • Table 85 : Qiagen N.V.: Product Portfolio
  • Table 86 : Sysmex Corp.: Annual Revenue, 2023
  • Table 87 : Sysmex Corp.: Recent Developments, 2021-2023
  • Table 88 : Sysmex Corp.: Product Portfolio

List of Figures

  • Summary Figure : Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 1 : Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
  • Figure 2 : Rate of New Malignant Hematologic Cancers, by Age at Diagnosis, 2021
  • Figure 3 : Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 4 : Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, 2021-2028
  • Figure 5 : Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, 2021-2028
  • Figure 6 : Global Market for Next Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, 2021-2028
  • Figure 7 : Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, 2021-2028
  • Figure 8 : Global Market for Minimal Residual Disease Testing, by Application, 2021-2028
  • Figure 9 : Distribution Share of Estimated New Cases of Hematological Malignancies, 2021
  • Figure 10 : Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, 2021-2028
  • Figure 11 : Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, 2021-2028
  • Figure 12 : Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, 2021-2028
  • Figure 13 : Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, 2021-2028
  • Figure 14 : Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, 2021-2028
  • Figure 15 : Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, 2021-2028
  • Figure 16 : Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, 2021-2028
  • Figure 17 : Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, 2021-2028
  • Figure 18 : Global Market for Minimal Residual Disease Testing for Solid Tumors, by Region, 2021-2028
  • Figure 19 : Global Market for Minimal Residual Disease Testing for Other Applications, by Region, 2021-2028
  • Figure 20 : Global Market for Minimal Residual Disease Testing, by Region, 2021-2028
  • Figure 21 : U.S. Elderly (65 and Above) Population, 2010-2050
  • Figure 22 : 5-Year Relative Survival for Malignant Hematologic Cancers, by Cancer Type, 2022
  • Figure 23 : North American Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 24 : North American Market for Minimal Residual Disease Testing, by Application, 2021-2028
  • Figure 25 : North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
  • Figure 26 : European Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 27 : European Market for Minimal Residual Disease Testing, by Application, 2021-2028
  • Figure 28 : European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
  • Figure 29 : Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 30 : Asia-Pacific Market for Minimal Residual Disease Testing, by Application, 2021-2028
  • Figure 31 : Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
  • Figure 32 : Rest of the World Market for Minimal Residual Disease Testing, by Technology, 2021-2028
  • Figure 33 : Rest of the World Market for Minimal Residual Disease Testing, by Application, 2021-2028
  • Figure 34 : Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
  • Figure 35 : Snapshot: Key ESG Trends in Minimal Residual Disease Testing Industry
  • Figure 36 : M&A in Minimal Residual Disease Testing Industry, by Year, 2020-2023
  • Figure 37 : Leading Market Players Ranking, 2022
  • Figure 38 : Global Minimal Residual Disease Testing Market Share, Competitive Intelligence, 2020-2023
  • Figure 39 : Adaptive Biotechnologies Corp.: Annual Revenue, 2021 and 2022
  • Figure 40 : Adaptive Biotechnologies Corp.: Revenue Share, by Business Unit, 2021
  • Figure 41 : Amgen Inc.: Annual Revenue, 2021 and 2022
  • Figure 42 : Amgen Inc.: Revenue Share, by Product, 2022
  • Figure 43 : Amgen Inc.: Revenue Share, by Geography, 2022
  • Figure 44 : AstraZeneca Plc.: Annual Revenue, 2021 and 2022
  • Figure 45 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
  • Figure 46 : AstraZeneca Plc: Revenue Share, by Region, 2022
  • Figure 47 : Bio-Rad Laboratories Inc.: Annual Revenue, 2021 and 2022
  • Figure 48 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, 2022
  • Figure 49 : Bio-Rad Laboratories Inc.: Revenue Share, by Region, 2022
  • Figure 50 : Exact Sciences Corp.: Annual Revenue, 2020 and 2021
  • Figure 51 : Exact Sciences Corp.: Revenue Share, by Business Unit, 2022
  • Figure 52 : Guardant Health Inc.: Annual Revenue, 2021 and 2022
  • Figure 53 : Guardant Health Inc.: Revenue Share, by Business Unit, 2022
  • Figure 54 : Guardant Health Inc.: Revenue Share, by Region, 2022
  • Figure 55 : Illumina Inc.: Annual Revenue, 2021 and 2022
  • Figure 56 : Illumina Inc.: Revenue Share, by Business Unit, 2022
  • Figure 57 : Illumina Inc.: Revenue Share, by Region, 2022
  • Figure 58 : Invitae: Annual Revenue, 2021 and 2022
  • Figure 59 : Invitae: Revenue Share, by Business Unit, 2022
  • Figure 60 : Invitae: Revenue Share, by Product, 2022
  • Figure 61 : Natera Inc.: Annual Revenue, 2021 and 2022
  • Figure 62 : Natera Inc.: Revenue Share, by Business Unit, 2022
  • Figure 63 : Natera Inc.: Revenue Share, by Region, 2022
  • Figure 64 : NeoGenomics Inc.: Annual Revenue, 2021 and 2022
  • Figure 65 : NeoGenomics Inc.: Revenue Share, by Business Unit, 2022
  • Figure 66 : Qiagen N.V.: Annual Revenue, 2021 and 2022
  • Figure 67 : Qiagen N.V.: Revenue Share, by Business Unit, 2022
  • Figure 68 : Qiagen N.V.: Revenue Share, by Region, 2022
  • Figure 69 : Sysmex Corp.: Annual Revenue, 2022 and 2023
  • Figure 70 : Sysmex Corp.: Revenue Share, by Region, 2023